+193.3%
IEFA vs GSK
+115.1%
+78.2%
-34.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.1% | -1.3% | +0.3% | -0.5% |
| 7D | -4.2% | -3.1% | -1.0% | -3.0% |
| 30D | -2.7% | -0.9% | -1.8% | -2.5% |
| 3M | -6.5% | -4.2% | -2.3% | -5.3% |
| 6M | -1.3% | -1.6% | +0.3% | -1.4% |
| YTD | +6.1% | +2.6% | +3.5% | +3.5% |
| 1Y | +11.8% | +6.2% | +5.6% | +7.6% |
| 3Y | +54.1% | +55.0% | -0.9% | +21.8% |
| 5Y | +43.0% | +42.8% | +0.1% | +15.0% |
| 10Y | +141.3% | +102.1% | +39.2% | +58.0% |
| All | +193.3% | +115.1% | +78.2% | +82.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling